$10 Billion Deal, page-2877

I have nothing to discuss with BIT's management. I think their strategy of shelving BIT225 after the last failed trial and concentrating on the new preclinical programs is the way to go. Bringing on a world expert on HBV on to the board was wise now they are going to focus on this area.

I have said many times my complaint is not with BIT's science, but with the shareholders who continue to believe that BIT225 is going somewhere. BIT has very clearly told you guys that BIT225 is on the shelf and the future is HBV, but many of you continue to cling on with hope that a $10 billion deal is going to drop any day. It is not.

I do think that BIT has not exactly made it easy for you shareholders to understand the change in direction, but they have not hidden anything from you. Open your eyes and read the announcements carefully.